<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305837</url>
  </required_header>
  <id_info>
    <org_study_id>2010-370</org_study_id>
    <secondary_id>2010-024561-43</secondary_id>
    <nct_id>NCT01305837</nct_id>
  </id_info>
  <brief_title>Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis</brief_title>
  <acronym>COMTiMS</acronym>
  <official_title>Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cyclic oral methylprednisolone once every&#xD;
      month has an effect on the intrathecal inflammation in patients suffering from progressive&#xD;
      multiple sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central&#xD;
      nervous system (CNS). It is presumably T-cell mediated and it is the most common&#xD;
      non-traumatic cause of disability affecting young people. 85 % of the MS causes starts out as&#xD;
      relapsing remitting MS (RRMS) and 15 % as primary progressive MS (PPMS). It has been found&#xD;
      that after 10 years 40-45 % of the RRMS patients will convert to a more progressive state of&#xD;
      disease, secondary progressive MS (SPMS).&#xD;
&#xD;
      Until recently it has been believed that the progression seen in MS occurred because of&#xD;
      axonal loss and neurodegeneration could occur independently of inflammation. Now&#xD;
      neuropathology studies shows that there is a close association between inflammation and&#xD;
      neurodegeneration in all stages of MS - also the progressive forms of MS.&#xD;
&#xD;
      Osteopontin (OPN) is an extracellular matrix protein with chemokine, cytokine and intergrin&#xD;
      properties. It has multiple immunological functions and is secreted by activated macrophages,&#xD;
      leukocytes and activated T lymphocytes. It is present in extracellular fluids and is&#xD;
      up-regulated at sites of inflammation. Increased levels of OPN where reported in the&#xD;
      cerebrospinal fluid (CSF) in patients with MS.&#xD;
&#xD;
      The main aim of this study is to analyze the effect of cyclic oral methylprednisolone on the&#xD;
      intrathecal inflammation in patients suffering from progressive multiple sclerosis measured&#xD;
      by OPN in the CSF. Second the investigators will look at other aims of intrathecal&#xD;
      inflammation, neurodegeneration, demyelination and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CSF osteopontin</measure>
    <time_frame>baseline and week 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>aims for clinical progression</measure>
    <time_frame>baseline and week 60</time_frame>
    <description>Change in expanded disability status scale (EDSS)&#xD;
Change in Timed 25-foot Walk (T25FW)&#xD;
Change in Multiple sclerosis impairment scale (MSIS)&#xD;
Change in multiple sclerosis functional composite (MSFC)&#xD;
Change in short form 36 (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aims for demyelination and disease activity</measure>
    <time_frame>baseline, week 12 (only MRI aims and MEP) and week 60</time_frame>
    <description>1. Change in the concentration of neurofilament heavy chain (NfH) in CSF 2. Change in the concentration of myelin basic protein (MBP) i CSF 3. Change in normalised brain volume (NBV), grey matter volume (GMV) og white matter volume (WMV) 4. Change in MTR og DTI i hele hjernen, lesions, normal appearing grey matter (NAGM) og normal appearing white matter (NAWM) 5. MEP (motor evoked potentials)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aims of intrathecal inflammation</measure>
    <time_frame>baseline and week 60</time_frame>
    <description>Change in cellcount i CSF&#xD;
Change in IgG-index&#xD;
Change in the concentration of nitric oxid (NO) metabolittes in CSV&#xD;
Change in CSV-serum albumin qvotient&#xD;
Change in the concentration of CXCL13 i CSF&#xD;
Change in the concentration of MMP-9 i CSF&#xD;
Number of new Gd-enhancing lessions on MRI&#xD;
Volume of T2 lessions on MRI&#xD;
Number of new or bigger T2 lessions on&#xD;
Change in MTR in the hole brain, in lessions, grey matter og white matter&#xD;
Change in DTI the hole brain, in lessions, grey matter og white matter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>screnning, baseline, week 12, 24, 36, 48, 60</time_frame>
    <description>physical examination, blood pressure, pulse, DEXA scan, bloodtests</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patients will be treated with the active drug methylprednisolone 500 mg in 3 days every month for 60 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>500 mg of methylprednisolone taken in 3 days every month</description>
    <arm_group_label>methylprednisolone</arm_group_label>
    <other_name>Medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 65 years old&#xD;
&#xD;
          -  Progressive form of MS (Eg. primary or secondary progressive MS)&#xD;
&#xD;
          -  Duration of progressive phase at least 1 year&#xD;
&#xD;
          -  Progression of at least 1 EDSS point for the last 2 years or at least ½ EDSS point in&#xD;
             patients with EDSS &gt; 5,5&#xD;
&#xD;
          -  Progressin in 2 FS point&#xD;
&#xD;
          -  EDSS &lt;/= 6,5&#xD;
&#xD;
          -  Signed informed consent and written authority&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
&#xD;
          -  Lack of secure contraception for women of child-bearing age (hormonal or intrauterine&#xD;
             device)&#xD;
&#xD;
          -  Attack in the last month previous to inclusion&#xD;
&#xD;
          -  Treatment with methylprednisolone or cyclic methylprednisolone the 3 previous month&#xD;
             before inclusion&#xD;
&#xD;
          -  Treatment with interferon-beta, Glatiramer acetate, immunglobulin G or other&#xD;
             immunomodulating treatment the 3 previous month before inclusion&#xD;
&#xD;
          -  Treatment with Mitoxantrone, ciclofosfamide, Azathioprin or other immunosuppressive&#xD;
             treatment the 6 previous month before inclusion&#xD;
&#xD;
          -  Previous treatment with drugs which the treating physician finds could have influence&#xD;
             on the study results&#xD;
&#xD;
          -  Diseases associated with immune defects&#xD;
&#xD;
          -  Treatment with other anticoagulant than acetyl salicyl acid&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Renal insufficiency or S-Creatinine &gt; 150 mmol/l&#xD;
&#xD;
          -  Acute or chronic infections with hepatitis B og C virus, HIV or other infections which&#xD;
             the treating physician finds relevant&#xD;
&#xD;
          -  Psychiatric illness or other conditions which can impair the collaboration of the&#xD;
             patient participating in the study&#xD;
&#xD;
          -  Contra-indication to MRI&#xD;
&#xD;
          -  Hypersensitivity to methylprednisolone&#xD;
&#xD;
          -  Osteoporosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rikke Ratzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scleroseklinikken, Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per S Sørensen, Professor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scleroseklinikken, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scleroseklinikken, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>July 10, 2013</last_update_submitted>
  <last_update_submitted_qc>July 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Rikke Ratzer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>methylprednisolone</keyword>
  <keyword>osteopontin</keyword>
  <keyword>inflammation</keyword>
  <keyword>demyelinating</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

